LifeSprout Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
2ndary - Private
- Investors
-
12
LifeSprout General Information
Description
Developer of synthetic soft tissue substitutes designed to be used for aesthetic and reconstructive medicine in tissue reproduction. The company's tissue substitutes focus on the regrowth of human tissue by transferring tissue from one part of the body to another, enabling doctors to repair patients' soft tissue damage from trauma, natural aging, surgery, cancer, and metabolic disease
Contact Information
Website
www.lifesproutbio.comCorporate Office
- 101 West Dickman Street
- Suite 900
- Baltimore, MD 21230
- United States
Corporate Office
- 101 West Dickman Street
- Suite 900
- Baltimore, MD 21230
- United States
LifeSprout Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 8. Later Stage VC (Series A) | 31-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 7. Secondary Transaction - Private | 13-Aug-2020 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series A) | 27-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 5. Debt - PPP | 16-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 06-Mar-2019 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 2. Grant | 01-Oct-2017 | $1.42M | $305K | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 01-Jul-2016 | $305K | $305K | Completed | Startup |
LifeSprout Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
LifeSprout Patents
LifeSprout Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4665784-A1 | Collagen-hydrogel composite | Pending | 15-Feb-2023 | ||
| WO-2024172909-A1 | Collagen-hydrogel composite | Inactive | 15-Feb-2023 | ||
| WO-2024172909-A9 | Collagen-hydrogel composite | Inactive | 15-Feb-2023 | ||
| EP-4665295-A1 | Modified crosslinked polymers | Pending | 15-Feb-2023 | ||
| US-20260234310-A1 | Modified crosslinked polymers | Pending | 15-Feb-2023 | C08F251/00 |
LifeSprout Signals
LifeSprout Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Medytox Venture Investment | Corporate Venture Capital | Minority | ||
| Nexus Management | Corporation | Minority | ||
| Redmile Group | Venture Capital | Minority | ||
| Kairos Ventures | Venture Capital | Minority | ||
| Medytox | Corporation | Minority |
LifeSprout FAQs
-
When was LifeSprout founded?
LifeSprout was founded in 2015.
-
Where is LifeSprout headquartered?
LifeSprout is headquartered in Baltimore, MD.
-
What is the size of LifeSprout?
LifeSprout has 21 total employees.
-
What industry is LifeSprout in?
LifeSprout’s primary industry is Drug Discovery.
-
Is LifeSprout a private or public company?
LifeSprout is a Private company.
-
What is LifeSprout’s current revenue?
The current revenue for LifeSprout is .
-
How much funding has LifeSprout raised over time?
LifeSprout has raised $35.3M.
-
Who are LifeSprout’s investors?
Medytox Venture Investment, Nexus Management, Redmile Group, Kairos Ventures, and Medytox are 5 of 12 investors who have invested in LifeSprout.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process